CN102558183B - Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound - Google Patents
Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound Download PDFInfo
- Publication number
- CN102558183B CN102558183B CN201010579341.0A CN201010579341A CN102558183B CN 102558183 B CN102558183 B CN 102558183B CN 201010579341 A CN201010579341 A CN 201010579341A CN 102558183 B CN102558183 B CN 102558183B
- Authority
- CN
- China
- Prior art keywords
- pyrrolidine
- carboxylic acid
- oxo
- pyrazolyl
- acid compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound Chemical class 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000000814 tuberculostatic agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 17
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 abstract description 7
- 229960003702 moxifloxacin Drugs 0.000 abstract description 7
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 6
- 229960003405 ciprofloxacin Drugs 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 241000192125 Firmicutes Species 0.000 abstract description 2
- 229940121657 clinical drug Drugs 0.000 abstract description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 12
- 238000003756 stirring Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 5
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 150000007660 quinolones Chemical class 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JHTKOUJDEUQFOB-UHFFFAOYSA-N 1h-pyrazol-1-ium;chloride Chemical compound Cl.C=1C=NNC=1 JHTKOUJDEUQFOB-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 101710186981 DNA gyrase subunit A Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound with the structural formula (I). The experiments show that the gram-positive bacteria resisting effect of the pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound is equal or superior to that of moxifloxacin and ciprofloxacin, and particularly the clinical-drug and pan-drug resistant bacillus activity resisting of the pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound is quite strong.
Description
Technical field
The invention belongs to pharmaceutical chemistry field, be specifically related to a kind of pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound and its production and use.
Background technology
The main trend of current Comprecin research is:
The breakthrough of fundamental research: the fundamental research of relevant quinolones will further be deepened.For example, all may there be important breakthrough structure activity relationship, mechanism of action, resistance mechanism, drug interaction, cytotoxicity and the new aspects such as screening model.And along with going deep into of fundamental research, will promote the development process of this class medicine.
Anti-microbial property further perfect: various countries are the high reactivities that had both retained anti-Gram-negative bacteria at its common feature of Novel Quinolone medicine grinding at present, obviously strengthened again resisting gram-positive bacteria active, and anerobe, mycoplasma, chlamydozoan have also been had certain effect.And along with going deep into that people are familiar with quinolones mechanism of action, will there is the compound higher to some specified germ activity.Further going deep into of drug drug interaction research, it will be more and more extensive making this class medicine and other drug drug combination treat some intractable infection.As Sitafloxacin itself does not have anti-mycotic activity, but it and amphotericin B, fluconazole or rice bran azoles etc. have obvious synergy.
Overcome resistance research: in recent years illustrate Comprecin resistance mechanism and mainly contain 3 points: (1) DNA gyrase subunit A or topoisomerase variation; (2) efflux body system strengthens; (3) outer membrane permeability declines.
Reduce phototoxicity, improve security: along with the appearance of the deep and new variety of studying, people have not only illustrated the structure activity relationship of this class medicine, also understand gradually the relation of its structure-untoward reaction, develop on this basis that anti-microbial property is better, the higher medicine of security.As 8 of quinolone female rings, introduce methoxyl groups or difluoro-methoxy (as Moxifloxacin, Gatifloxacin, Jia Nuosha magnitude) makes its phototoxicity be reduced to bottom line, improved security.
Widening of Application Areas: the oriented antiviral trend of extending with anti-tumor aspect of the research and development of quinolones in recent years.
The present invention be intended to design, prepare and find from above several aspects there is brand new and quinolones high-efficiency low-toxicity can property of medicine compound.
Summary of the invention
The object of the invention is on the basis of existing technology, a kind of pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound is provided.
Another object of the present invention is to provide the preparation method of above-claimed cpd.
Another object of the present invention is to provide the purposes of above-claimed cpd aspect medicinal.
Object of the present invention can reach by following measures:
The fluoro-7-of compound 1-cyclopropyl base-6-shown in a kind of formula (I) (2-hydroxyethyl-3-is amino) Pyrrolidine [3,4-c] pyrazoles-5-base-8-methoxyl group-Isosorbide-5-Nitrae-dihydro-4-Oxoquinoline-3-carboxylic acid, it has following structure:
The preparation method of above-claimed cpd is: formula (II) compound is reacted to preparation formula (I) compound with formula (III) compound under alkaline condition, and its reaction scheme is as follows:
The temperature of reaction of its Chinese style (II) compound and formula (III) compound is 20～50 ℃, and reaction solvent is acetonitrile, and alkaline condition is triethylamine.
Formula (II) compound reacts preparation by 1-tertbutyloxycarbonyl-3-cyano group-4-pyrrolidone in ethanol at 20～30 ℃ with hydroxyethyl.
First boric acid and diacetyl oxide are heated to 100～120 ℃ of reactions, react and in backward reaction system, add 1-cyclopropyl-6,7-difluoro-8-methoxyl-Isosorbide-5-Nitrae-dihydro-4-oxo-quinoline-3-carboxylic acid ethyl ester, then at 100～120 ℃, react preparation formula (III) compound.
Compound of the present invention can be applicable to prepare antibiotic or antitubercular agent, experiment find this compound to the anti-microbial effect of trial gram positive organism basic and Moses, encircle third quite or more excellent, and to tubercule bacillus, particularly the general resistance bacillus of clinical drug-resistant has great activity.
Embodiment
The preparation of amino Pyrrolidine [3, the 4-c] pyrazole hydrochloride of embodiment 1,2-hydroxyethyl-3-(II)
Under nitrogen protection, the mixture of 1-tertbutyloxycarbonyl-3-cyano group-4-pyrrolidone (1.05g, 5.0mmol), 98% hydroxyethyl (0.42g, 5.5mmol) and ethanol (20ml) reacts 12h in stirring at room.React complete solvent evaporated, gained resistates is dissolved in ethyl acetate (20ml), uses saturated common salt water washing, anhydrous magnesium sulfate drying.Filter, the resistates after concentrating is dissolved in methyl alcohol (10ml), passes into dry HCl gas, and TLC follows the tracks of until react completely.The solid that filtration is separated out, vacuum-drying obtains off-white color solid 0.33g (yield 27.4%).
1H-NMR(400MHz，DMSO-d
6)δ
ppm：3.64-3.67(2H，m，pyrrolidine)，3.97-3.98(2H，m，pyrrolidine)，4.08(2H，br，N
CH 2 CH
2OH)，4.17(2H，m，NCH
2 CH 2 OH)，MS(ESI，m/z)：169(M+H)
+
Embodiment 2,1-cyclopropyl-6,7-difluoro-8-methoxyl-Isosorbide-5-Nitrae-dihydro-4-Oxoquinoline-3-carboxylic acid root-O
3, O
4the preparation of-diethyl acid group boron (III)
The mixture of boric acid (1.50g, 24.2mmol) and diacetyl oxide (8mL, 80.0mmol) is heated to 110 ℃, stirring reaction 1.5h.Temperature of reaction is down to 50～60 ℃, adds 1-cyclopropyl-6,7-difluoro-8-methoxyl-1 in reaction system, 4-dihydro-4-oxo-quinoline-3-carboxylic acid ethyl ester (4.55g, 14.1mmol), then be warming up to 110 ℃, continue to stir, TLC follows the tracks of reaction process, and 6h reaction is finished.Be down to room temperature, in the frozen water (200mL) under the slow impouring of reaction solution is fully stirred, continue to filter after stirring 0.5h, filter cake water fully washs, then uses appropriate ethanol rinsing, dry, obtains white powder solid (5.21g, 90.1%).
1H NMR(500MHz，CDCl
3)δ
ppm：1.20-1.45(4H，m，2×cyclopropylCH
2)，2.03(6H，s，2×COCH
3)，4.40-4.42(1H，m，cyclopropylCH)，4.22(3H，s，OCH
3)，8.10(1H，d，J＝9.0Hz，C
5-H)，9.21(1H，s，C
2-H)
The preparation of embodiment 3, the fluoro-7-of 1-cyclopropyl-6-(2-hydroxyethyl-3-amino-pyrazol [3,4-c] Pyrrolidine base)-8-methoxyl group-Isosorbide-5-Nitrae-dihydro-4-Oxoquinoline-3-carboxylic acid (I)
Under nitrogen protection; the amino Pyrrolidine [3 of 2-hydroxyethyl-3-; 4-c] pyrazole hydrochloride (0.36g; 1.5mmol), after the mixture stirring at room 10min of acetonitrile (10mL) and triethylamine (1.0mL), add 1-cyclopropyl-6; 7-difluoro-8-methoxyl-Isosorbide-5-Nitrae-dihydro-4-Oxoquinoline-3-carboxylic acid root-O
3, O
4-diethyl acid group boron (0.41g, 1.0mmol), 40 ℃ of reacting by heating after continuation stirring 1h, TLC follows the tracks of reaction process, and 36h reaction is complete.Evaporated under reduced pressure after the separation of decompression silicagel column, gained brown color solid is dissolved in 7% aqueous sodium hydroxide solution (10mL), at 40 ℃, stirs, and TLC follows the tracks of reaction process, and 30min reaction is complete.Be down to room temperature, with 5% hydrochloric acid, adjust pH=5～6, after stirring 0.5h, filter, dry, obtain off-white color solid (0.19g, 42.8%).
1H-NMR(400MHz，DMSO-d6)δppm：1.02-1.12(4H，m，2×cyclopropyl CH2)，3.58(3H，s，OCH3)，3.64-3.68(2H，m，pyrrolidine)，3.88-3.91(2H，m，pyrrolidine)，4.15-4.19(1H，m，cyclopropyl CH)，4.53-4.54(4H，m，NCH2CH2OH)，7.72(1H，d，J＝13.6Hz，C5-H)，8.68(1H，s，C2-H)，MS(ESI，m/z)：444(M+H)
+
Effect experiment
Antibiotic and the tuberculosis of the compounds of this invention is active is to realize by measuring its minimum inhibitory concentration (MIC, mg/L) to reference culture, clinical isolates strain.
Bacterium minimum inhibitory concentration is measured as follows: adopt plate doubling dilution and Denlay multi-point inoculator to carry out drug sensitive experiment, experimental bacteria increases bacterium with nutrient broth and angry heart immersion liquid; After medicine dissolution, with the doubling dilution of MH meat soup, become various desired concns, add respectively in right amount in plate, MH nutrient agar dissolves in rear quantitative injection pastille liquid plate and mixes, the final concentration of medicine is respectively 0.03,0.06,0.125......128 μ g/ml, in plate after culture medium solidifying with multi-point inoculator inoculation experiments bacterium (10
5cfu/ point), put 35 ℃ of constant temperature culture observations after 18 hours, in the plate of asepsis growth, the concentration of contained drug minimum is minimum inhibitory concentration (MIC).
Tubercule bacillus activity test method: instrument and reagent: BacT/Alert system, mycobacterium culturing bottle (MB).Trial drug preparation: Rifampin (RIF) solvent dehydrated alcohol, diluent distilled water, vazadrine (INH), Tibutol (EMB), Moxifloxacin, Ciprofloxacin (CIP) solvent, the equal distilled water of diluent; The ultimate density 0.12-128ug/ml of medicine in each culturing bottle.The preparation of former times of bacteria suspension: after the positive reaction of MB bottle, positive MB bottle concussion is broken up to bacterium (in 36 hours); Former times of bacteria suspension of the preparation of 1% former times of bacteria suspension: 0.1ml adds in 10mlMB bottle.Interpretation standard growth control has two kinds of modes, a kind of is direct growth control, as operation index, bacterial concentration is former times of bacteria suspension, another kind is 1% growth control, bacterial concentration is 1% former times of bacteria suspension, as interpretation Rifampin (RIF), and the index of vazadrine (INH), Tibutol (EMB), Moxifloxacin, Ciprofloxacin (CIP) result.
Result judgement:
1.GC bottle presents and positive within latter two days, include medicine bottle and be also positive, and represents that this medicine is invalid.
2.GC bottle presents the positive two days later, containing medicine bottle, is just positive (not generally being), represents this susceptibility sense.
Table 1 has been listed some representation compounds in the application's formula I compound antibacterial activity in vitro to various gram-positive microorganisms and negative bacterium, and compares with two Comprecin Moxifloxacins, Ciprofloxacins.
Table 1, MIC (ug/ml)
| Compound | Embodiment 3 | Moxifloxacin | Ciprofloxacin |
| Klebsiella Pneumoniae | 0.5 | 0.5 | 1.0 |
| Klebsiella Pneumoniae | 1.0 | 1.0 | 2.0 |
| Klebsiella Pneumoniae (ESBL+AMPC) | 4.0 | 8.0 | 64.0 |
| Klebsiella Pneumoniae (ESBL+AMPC) | 4.0 | 8.0 | 128 |
| Klebsiella Pneumoniae (ESBL+AMPC) | 4.0 | 8.0 | 64.0 |
| Escherichia coli | 0.5 | 0.5 | 0.5 |
| Escherichia coli | 0.5 | 0.5 | 0.5 |
| Escherichia coli (ESBL+AMPC) | 8.0 | 8.0 | 128.0 |
| Escherichia coli (ESBL+AMPC) | 8.0 | 8.0 | 128.0 |
| Escherichia coli (ESBL+AMPC) | 8.0 | 8.0 | 128.0 |
| Streptococcus aureus (MSSA) | 0.25 | 0.25 | 1.0 |
| Streptococcus aureus (MSSA) | 0.5 | 0.5 | 0.5 |
| Streptococcus aureus (MRSA) | 2.0 | 2.0 | 64.0 |
| Streptococcus aureus (MRSA) | 1.0 | 2.0 | 128.0 |
| Streptococcus aureus (MRSA) | 2.0 | 2.0 | 64.0 |
| ATCC29213 | 0.25 | 0.12 | 0.5 |
| ATCC35218 | 0.25 | 0.5 | 0.5 |
Table 2 embodiment 3 compounds and 4 kinds of antibacterials are to the MIC of mycobacterium tuberculosis (ug/ml)
| Antibacterials | H37Rv ATCC27294 | Tubercule bacillus (clinical strain MDR926) |
| Vazadrine | 0.12 | 64.0 |
| Rifampin | 2.0 | ＞256.0 |
| Tibutol | 1.0 | 128.0 |
| Moxifloxacin | 0.25 | 1.0 |
| Embodiment 3 | 0.12-0.25 | 0.5-1.0 |
H37Rv ATCC27294 standard Quality Control bacterial strain
The clinical general Resistant strain of tubercule bacillus (clinical strain MDR926)
The acute toxicity comparison of table 3 embodiment 3 compounds and Moxifloxacin
Claims (3)
1. the compound shown in formula (I),
2. the application of compound claimed in claim 1 aspect preparation antibacterials.
3. compound claimed in claim 1 is in the application of preparing aspect antitubercular agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010579341.0A CN102558183B (en) | 2010-12-08 | 2010-12-08 | Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010579341.0A CN102558183B (en) | 2010-12-08 | 2010-12-08 | Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102558183A CN102558183A (en) | 2012-07-11 |
| CN102558183B true CN102558183B (en) | 2014-02-05 |
Family
ID=46404928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010579341.0A Active CN102558183B (en) | 2010-12-08 | 2010-12-08 | Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102558183B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145615B (en) * | 2013-03-20 | 2015-07-29 | 浙江医药股份有限公司 | A kind of post-treating method of Nai Nuosha star inner complex |
| CN108239098B (en) * | 2016-12-26 | 2021-01-12 | 中国医学科学院药物研究所 | Benzoxazine oxazolidinone compound containing tetrahydropyridine and preparation method and application thereof |
-
2010
- 2010-12-08 CN CN201010579341.0A patent/CN102558183B/en active Active
Non-Patent Citations (6)
| Title |
|---|
| Xin Guo et al..Synthesis and in vitro antibacterial activities of aminopyrrolo[3,4-c]pyrazol-5(2H,4H,6H) -yl)quinolone derivatives.《chinese chemical letters》.2010,第21卷(第10期),1141-1144. |
| Xin Guo et al..Synthesis and in vitro antibacterial activities of aminopyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)quinolone derivatives.《chinese chemical letters》.2010,第21卷(第10期),1141-1144. * |
| 加替沙星合成工艺改进研究;李倩 等;《精细化工中间体》;20091028;第39卷(第5期);37-69 * |
| 加替沙星的合成研究;周文 等;《中南药学》;20101020;第8卷(第10期);751-753 * |
| 周文 等.加替沙星的合成研究.《中南药学》.2010,第8卷(第10期),751-753. |
| 李倩 等.加替沙星合成工艺改进研究.《精细化工中间体》.2009,第39卷(第5期),37-69. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102558183A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106518828B (en) | Amides myricetin derivative, preparation method and application | |
| CN101193882B (en) | N-formyl hydroxylamine compounds as PDF inhibitor | |
| CN102558183B (en) | Pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound | |
| CN110041306B (en) | 4-hydroxy-2-quinolone-N- (4-quinazolinone) -3-carboxamide derivatives | |
| CN103992337B (en) | A kind of method preparing Aspoxicillin sodium easily | |
| CN106749213B (en) | A kind of indole derivatives and preparation method with 1,2,4- oxadiazoles structure and the application in preparation antibacterials | |
| CN105218537A (en) | Berberine benzimidazoles compound or its pharmacologically acceptable salt and its preparation method and application | |
| CN105622492A (en) | Chalcone derivatives with drug-resistant bacteria resistance activity | |
| CN107141255A (en) | Enrofloxacin calcium chelate and its synthetic method and application | |
| CN105669671A (en) | Preparation method of moxifloxacin hydrochloride | |
| HU204056B (en) | Process for producing new azetidine derivatives | |
| CN106967093B (en) | A kind of cephalosporin compound and its preparation method and application | |
| CN102627642A (en) | Metal complexes of moxifloxacin and pharmaceutical purpose thereof | |
| CN104098588A (en) | Tricyclic quinolone derivative, preparation method and application thereof | |
| CN101450938B (en) | 7-(4-oximido-3-amido-3-alkyl-1-piperidine)quinoline carboxylic acid derivates and preparation method thereof | |
| CN101993449A (en) | Preparation methods of high-purity cefotiam hexetil and dihydrochloride of high-purity cefotiam hexetil | |
| Nasser et al. | Synthesis, characterization, and antibacterial assessment of new gatifloxacin analogues | |
| CN108047216B (en) | 3, 4-diphenylpyrazole compound and preparation and application thereof | |
| CN101108835B (en) | Method of manufacturing high purity hydrochloric acid sarafloxacin | |
| CN108456157B (en) | 1-substituted benzoyl-4-fatty acyl semicarbazide derivatives, preparation method and application as antibacterial drugs | |
| CN111135182B (en) | Antibacterial product and preparation method and application thereof | |
| RU2634122C1 (en) | Fluoroquinolones based on 4-deoxypyridoxine | |
| CN103483315A (en) | 7-(3-aminomethyl-4-alkoxyimino-1-piperidyl)-1-[(1R,2S)-2-fluorocyclopropyl] quinolone carboxylic acid compounds and preparation method thereof | |
| CN115260162A (en) | 3-hydroxy-4-pyridone-ciprofloxacin coupling compound and preparation method and application thereof | |
| CN102603731B (en) | One class Novel Quinolone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200123 Address after: 230000 No. 61 Science Avenue, Hefei High-tech Zone, Anhui Province Patentee after: Hefei Huawei Pharmaceutical Co.,Ltd. Address before: Dongshan Street run Qi Road Jiangning District of Nanjing City, Jiangsu Province, No. 99 210012 Patentee before: NANJING MESE PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240924 Address after: No. 99 Runqi Road, Dongshan Street, Jiangning District, Nanjing City, Jiangsu Province, 211100 Patentee after: NANJING MINGSHENG PHARMACEUTICAL Co.,Ltd. Country or region after: China Address before: 230000 61 science Avenue, high tech Zone, Hefei City, Anhui Province Patentee before: Hefei Huawei Pharmaceutical Co.,Ltd. Country or region before: China |